Cellebrite DI Ltd. (NASDAQ:CLBT) Receives $23.43 Average Price Target from Brokerages

Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) has received an average recommendation of "Buy" from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $23.43.

CLBT has been the topic of a number of research reports. JPMorgan Chase & Co. upped their price target on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Needham & Company LLC reiterated a "buy" rating and set a $28.00 target price on shares of Cellebrite DI in a research report on Monday, March 10th. Finally, Lake Street Capital raised their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, February 14th.

Hedge Funds Weigh In On Cellebrite DI

A number of institutional investors have recently modified their holdings of CLBT. Axon Enterprise Inc. purchased a new stake in Cellebrite DI in the 4th quarter worth approximately $198,270,000. FMR LLC boosted its holdings in shares of Cellebrite DI by 89.1% during the fourth quarter. FMR LLC now owns 10,621,344 shares of the company's stock worth $233,988,000 after purchasing an additional 5,004,587 shares during the last quarter. True Wind Capital Management L.P. grew its position in shares of Cellebrite DI by 18.2% in the fourth quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock valued at $305,358,000 after purchasing an additional 2,130,386 shares during the period. Invesco Ltd. acquired a new position in Cellebrite DI in the fourth quarter valued at $32,700,000. Finally, Principal Financial Group Inc. purchased a new position in Cellebrite DI during the third quarter worth about $23,402,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Remove Ads

Cellebrite DI Stock Performance

NASDAQ:CLBT traded down $0.66 during trading hours on Friday, hitting $19.95. The company's stock had a trading volume of 1,007,487 shares, compared to its average volume of 1,126,957. Cellebrite DI has a 52-week low of $10.25 and a 52-week high of $26.30. The business's 50-day moving average is $21.04 and its two-hundred day moving average is $19.85. The company has a market capitalization of $4.78 billion, a PE ratio of -14.35, a PEG ratio of 4.27 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, analysts predict that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.